Heat therapy with chemo and radiation for rectal cancer
Part of Cancer, Digestive system, Injuries & trauma clinical trials.
This trial tests if adding heat therapy (hyperthermia) to standard chemotherapy and radiation helps treat rectal cancer that has high-risk features. Heat therapy is thought to make cancer cells more sensitive to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is 0 to 12 cm from the anal opening (lower or middle part of the rectum).
- Your cancer has at least one high-risk feature, like being T4, N2, close to the mesorectal fascia, having involved lymph nodes, or EMVI positivity.
- You have not had prior treatment (chemotherapy, radiation, or major surgery) for rectal cancer.
- You are 18 or older and in good general health (able to do daily activities).
- You do not have distant metastases (cancer spread to other organs) or tumors with microsatellite instability (MSI-H).
- You do not have metal implants or a pacemaker that would prevent hyperthermia, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.